TVTX Stock Analysis: Travere Therapeutics | NASDAQ

Kidney Therapies, Metabolic Treatments, Oral Medications, Enzyme Replacement

Total Rating 41

Safety 42

Buy Signal 0.89

Biotechnology
Industry Rotation: +12.3

Market Cap: 6.34B
Avg Turnover: 82.3M

Risk 3d forecast

Volatility65.1%

VaR 5^th Pctl9.61%

VaR vs Median-8.44%

Reward TTM

Sharpe Ratio1.89

Rel. Str. IBD98.6

Rel. Str. Peer Group85.8

Character TTM

Beta2.127

Beta Downside1.053

Hurst Exponent0.434

Drawdowns 3y

Max DD63.50%

CAGR/Max DD1.06

CAGR/Mean DD2.85

EPS (Earnings per Share)

Last SUE: -0.96
Qual. Beats: -1

Revenue

Rev. CAGR: 68.69%
Rev. Trend: 96.3%

Last SUE: 0.46
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage

High Debt While Negative Cash Flow

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.6 years of data

Jan +3.0% 8

Feb +0.3% 14

Mar -4.6% 19

Apr +2.4% 5

May +0.3% 5

Jun +5.0% 20

Jul -0.1% 7

Aug +3.3% 2

Sep -2.8% 11

Oct +1.3% 2

Nov -0.7% 2

Dec +2.3% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TVTX Travere Therapeutics

Travere Therapeutics (NASDAQ: TVTX) is a U.S.-based biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. The company was formerly known as Retrophin, Inc. before rebranding in November 2020.

Its marketed products include FILSPARI (sparsentan), a once-daily oral therapy that targets two pathways (endothelin 1 and angiotensin-II) in IgA Nephropathy progression, and Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurrent kidney stones.

Traveres clinical-stage pipeline includes sparsentan, which holds Orphan Drug Designation in both the U.S. and Europe for focal segmental glomerulosclerosis (FSGS), and Pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria. The company also maintains a collaboration with PharmaKrysto Limited for pre-clinical work on its cystinuria program.

As a mid-cap biotechnology company in the rare disease space, Travere operates within a sector that often benefits from regulatory incentives such as FDA Orphan Drug Designation, which typically grants several years of market exclusivity for therapies addressing conditions affecting small patient populations.

Headlines to Watch Out For

FILSPARI commercial uptake drives revenue growth in IgA Nephropathy
FSGS regulatory decision for sparsentan supplemental NDA remains key catalyst
Cash burn widens as commercial launch spend and pipeline investment accelerate

Piotroski VR-10 (Strict) 2.5

Net Income: -43.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA 18.80 > 1.0
NWC/Revenue: 78.32% < 20% (prev 56.92%; Δ 21.40% < -1%)
CFO/TA 0.12 > 3% & CFO 92.7m > Net Income -43.5m
Net Debt (141.9m) to EBITDA (22.9m): 6.19 < 3
Current Ratio: 4.05 > 1.5 & < 3
Outstanding Shares: last quarter (93.5m) vs 12m ago 5.10% < -2%
Gross Margin: 94.41% > 18% (prev 96.89%; Δ -2.49% > 0.5%)
Asset Turnover: 87.30% > 50% (prev 60.12%; Δ 27.18% > 0%)
Interest Coverage Ratio: -4.27 > 6 (EBIT TTM -40.5m / Interest Expense TTM 9.48m)

Altman Z'' -2.87

A: 0.58 (Total Current Assets 615.1m - Total Current Liabilities 152.0m) / Total Assets 799.4m
B: -1.93 (Retained Earnings -1.54b / Total Assets 799.4m)
C: -0.06 (EBIT TTM -40.5m / Avg Total Assets 677.3m)
D: 0.03 (Book Value of Equity 24.5m / Total Liabilities 774.8m)
Altman-Z'' = -2.87 = D

Beneish M -2.47

DSRI: 1.18 (Receivables 80.6m/38.7m, Revenue 591.3m/333.9m)
GMI: 1.03 (GM 96.89% / 94.41%)
AQI: 0.75 (AQ_t 0.22 / AQ_t-1 0.29)
SGI: 1.77 (Revenue 591.3m / 333.9m)
TATA: -0.17 (NI -43.5m - CFO 92.7m) / TA 799.4m)
Beneish M = -2.47 (Cap -4..+1) = BBB

What is the price of TVTX shares?

As of September 04, 2026, the stock is trading at USD 66.54 with a total of 1,114,896 shares traded. Over the past week, the price has changed by -1.45%, over one month by +21.03%, over three months by +47.21% and over the past year by +239.32%.

Current recommended Stop Loss: 63.90 (which is 4% or 1.2 ATR below the current price).

Is TVTX a buy, sell or hold?

Travere Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy TVTX.

StrongBuy: 11
Buy: 2
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TVTX price?

Analysts Target Price	74.1	11.4%

Travere Therapeutics (TVTX) - Fundamental Data Overview as of 04 September 2026

Market Cap USD = 6.34b (6.34b USD * 1.0 USD.USD)
P/E Forward = 43.8596
P/S = 10.7168
P/B = 252.6237
Revenue TTM = 591.3m USD
EBIT TTM = -40.5m USD
EBITDA TTM = 22.9m USD
Long Term Debt = 602.8m USD (from longTermDebt, last quarter)
Short Term Debt = 6.16m USD (from shortTermDebt, last quarter)
Debt = 631.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.1m
Net Debt = 141.9m USD (calculated: Debt 631.0m - CCE 489.2m)
Enterprise Value = 6.48b USD (6.34b + Debt 631.0m - CCE 489.2m)
Interest Coverage Ratio = -4.27 (Ebit TTM -40.5m / Interest Expense TTM 9.48m)
EV/FCF = -924.7x (Enterprise Value 6.48b / FCF TTM -7.01m)
FCF Yield = -0.11% (FCF TTM -7.01m / Enterprise Value 6.48b)
FCF Margin = -1.18% (FCF TTM -7.01m / Revenue TTM 591.3m)
Net Margin = -7.35% (Net Income TTM -43.5m / Revenue TTM 591.3m)
Gross Margin = 94.41% ((Revenue TTM 591.3m - Cost of Revenue TTM 33.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev 78.96%)
Tobins Q-Ratio = 8.11 (Enterprise Value 6.48b / Total Assets 799.4m)
Interest Expense / Debt = 1.50% (Interest Expense 9.48m / Debt 631.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -32.0m (EBIT -40.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.86 (Total Current Assets 615.1m / Total Current Liabilities 159.5m)
Debt / Equity = 25.73 (Debt 631.0m / totalStockholderEquity, last quarter 24.5m)
Debt / EBITDA = 6.19 (Net Debt 141.9m / EBITDA 22.9m)
Debt / FCF = -20.24 (negative FCF - burning cash) (Net Debt 141.9m / FCF TTM -7.01m)
Total Stockholder Equity = 77.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.42% (Net Income -43.5m / Total Assets 799.4m)
RoE = -55.79% (Net Income TTM -43.5m / Total Stockholder Equity 77.9m)
RoCE = -5.94% (EBIT -40.5m / Capital Employed (Equity 77.9m + L.T.Debt 602.8m))
RoIC = -5.12% (negative operating profit) (NOPAT -32.0m / Invested Capital 623.9m)
WACC = 12.35% (E(6.34b)/V(6.97b) * Re(13.46%) + D(631.0m)/V(6.97b) * Rd(1.50%) * (1-Tc(0.21)))
Discount Rate = 13.46% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.08 | Cagr: 8.92%
[DCF] Fair Price = unknown (Cash Flow -7.01m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.96 | # QB: -1
Revenue Correlation: 96.30 | Revenue CAGR: 68.69% | SUE: 0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.51 | Chg30d=+29.43% | Revisions=+40% | Analysts=8
EPS current Year (2026-12-31): EPS=1.74 | Chg30d=-7.13% | Revisions=+0% | GrowthEPS=+90.7% | GrowthRev=+47.5%
EPS next Year (2027-12-31): EPS=5.67 | Chg30d=+16.94% | Revisions=+0% | GrowthEPS=+226.9% | GrowthRev=+49.5%
[Analyst] Revisions Ratio: +13% (up=7, down=5)